<DOC>
	<DOC>NCT02146846</DOC>
	<brief_summary>The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.</brief_summary>
	<brief_title>Population Pharmacokinetics of Imatinib in CML Patients in Iran</brief_title>
	<detailed_description>patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study then population pharmacokinetics parameters is determined.</detailed_description>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>patient in chronic phase of myeloid leukemia no liver and renal failure multiple dug treatment previous treatment of interferon patients in blast or accelerated phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cml</keyword>
</DOC>